Cargando…

Ovarian cancer stem cells and targeted therapy

BACKGROUND: Ovarian cancer has the highest ratio of mortality among gynecologic malignancies. Chemotherapy is one of the most common treatment options for ovarian cancer. However, tumor relapse in patients with advanced tumor stage is still a therapeutic challenge for its clinical management. MAIN B...

Descripción completa

Detalles Bibliográficos
Autores principales: Keyvani, Vahideh, Farshchian, Moein, Esmaeili, Seyed-Alireza, Yari, Hadi, Moghbeli, Meysam, Nezhad, Seyed-Reza Kazemi, Abbaszadegan, Mohammad Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896744/
https://www.ncbi.nlm.nih.gov/pubmed/31810474
http://dx.doi.org/10.1186/s13048-019-0588-z
Descripción
Sumario:BACKGROUND: Ovarian cancer has the highest ratio of mortality among gynecologic malignancies. Chemotherapy is one of the most common treatment options for ovarian cancer. However, tumor relapse in patients with advanced tumor stage is still a therapeutic challenge for its clinical management. MAIN BODY: Therefore, it is required to clarify the molecular biology and mechanisms which are involved in chemo resistance to improve the survival rate of ovarian cancer patients. Cancer stem cells (CSCs) are a sub population of tumor cells which are related to drug resistance and tumor relapse. CONCLUSION: In the present review, we summarized the recent findings about the role of CSCs in tumor relapse and drug resistance among ovarian cancer patients. Moreover, we focused on the targeted and combinational therapeutic methods against the ovarian CSCs.